Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción CKDXF?
El precio actual de CKDXF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Opthea Ltd?
Opthea Ltd pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Opthea Ltd?
La capitalización bursátil actual de Opthea Ltd es $0
¿Es Opthea Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 5 analistas han realizado calificaciones de análisis para Opthea Ltd, incluyendo 0 fuerte compra, 1 compra, 3 mantener, 4 venta, y 0 fuerte venta
